leisure time -WSS

leisure time

author：hotspot 2025-10-01 21:10:29 - browse：3

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Apellis safety probe of eye disease drug centers on injection needle

WSS

What AAP's gender

NYU Langone launches private ChatGPT for its health care data

EU moves toward latest gene techniques in food production to counter climate change, shortages

As pharma fights Medicare drug negotiation, hospitals, docs silent

How Long Island became the ‘eugenics capital of the world’

2 million sign

explore

leisure time

explore

What does generative AI mean for health care? We asked experts

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Pope Francis asks Church to identify 21st

State Dept. review finds Biden bears some blame for Afghanistan failures

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

State Dept. review finds Biden bears some blame for Afghanistan failures

As pharma fights Medicare drug negotiation, hospitals, docs silent

hotspot

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

EU moves toward latest gene techniques in food production to counter climate change, shortages

Diversity in medical illustrations gets boost from Chidiebere Ibe

How a symptom of dementia informs our understanding of creativity

How to make AI work for medicine

As pharma fights Medicare drug negotiation, hospitals, docs silent

explore

hotspot

leisure time

leisure time